Ready 8-Ks
13
Latest filing
May 07, 2026 23:59 UTC
Top materiality
0.90
Event mix
earnings ×4 · leadership ×4 · other_material ×4
Sentiment
4 pos · 1 neg · 8 neu
Latest earnings
reported 2026-Q1
-
May 07, 2026 23:59 UTC
earnings
materiality 0.75
positive
item 2.02item 9.01
Iovance Q1 revenue $71M (+45% YoY); guides FY26 $350-370M; endometrial cancer 40% cORR
Total product revenue ~$71M in Q1 2026, up 45% YoY; U.S. Amtagvi revenue ~$60M, Proleukin ~$11M.
-
Feb 24, 2026 23:59 UTC
earnings
materiality 0.75
positive
item 2.02item 8.01item 9.01
Iovance Q4 product revenue $87M (30% QoQ), FY2025 $264M; FDA Fast Track for NSCLC
Q4 product revenue ~$87M, up ~30% QoQ; FY2025 total $264M, within $250-300M guidance.
-
Jan 09, 2026 23:59 UTC
other_material
materiality 0.65
neutral
item 8.01item 9.01
Iovance reaffirms FY2025 revenue guidance of $250-300M; cash $307M as of Q3
Expects to achieve previously disclosed FY2025 revenue guidance of $250-300M in first full year of Amtagvi sales.
-
Nov 06, 2025 23:59 UTC
earnings
materiality 0.70
positive
item 2.02item 9.01
Iovance Q3 revenue $68M (+13% QoQ), margin 43%; lifileucel NSCLC data durable
Q3 2025 product revenue ~$68M, up 13% sequentially; gross margin 43% on ~$39M cost of sales.
-
Aug 22, 2025 23:59 UTC
other_material
materiality 0.60
neutral
item 1.01item 9.01
Iovance Biotherapeutics enters $350M ATM equity offering agreement with Jefferies
Agreement with Jefferies LLC to sell up to $350M of common stock in at-the-market offerings.
-
Aug 19, 2025 23:59 UTC
regulatory
materiality 0.70
positive
item 8.01item 9.01
Iovance's Amtagvi receives Health Canada approval for advanced melanoma
Health Canada issued NOC/c for Amtagvi (lifileucel) for unresectable/metastatic melanoma after anti-PD-1 and targeted therapy.
-
Aug 07, 2025 23:59 UTC
earnings
materiality 0.90
neutral
item 2.02item 5.02item 9.01
Iovance reports Q2 2025 earnings: $60M revenue, appoints new CFO, extends cash runway into Q4 2026
Q2 2025 total product revenue $60.0M (Amtagvi $54.1M, Proleukin $5.9M), net loss $111.7M.
-
Jul 03, 2025 23:59 UTC
leadership
materiality 0.65
neutral
item 5.02
Iovance CFO Bellemin departs effective June 30; SVP Finance Rosinack named interim CFO
CFO Jean-Marc Bellemin's resignation accelerated from July 10 to June 30, 2025 by mutual agreement.
-
Jun 13, 2025 23:59 UTC
leadership
materiality 0.65
negative
item 5.02
Iovance CFO Jean-Marc Bellemin resigns effective July 10, 2025
Jean-Marc Bellemin, CFO and principal financial & accounting officer, resigns effective July 10, 2025.